Street View: Leqselvi's US launch to boost sales for India's Sun Pharma

July 15 (Reuters) - Sun Pharma SUN.NS, India's top drugmaker by revenue, launched its anti-baldness drug Leqselvi in the U.S., following the settlement of a patent dispute with Incyte Corp INCY.O

Shares up 0.6%; pharma index .NIPHARM trading flat

POTENTIAL $1 BLN OPPORTUNITY

Nuvama ("hold"; PT: 1,830 rupees) estimates $300-$400 mln annual sales from Leqselvi by FY30, with peak sales potential of $1 bln in future

Sees Leqselvi becoming U.S. blockbuster drug for co

Morgan Stanley ("overweight"; PT: 1,960 rupees) says Leqselvi's commercialisation in U.S. includes "aggressive" patient support programme, indicating Sun Pharma's intent to drive early adoption amid competition from Pfizer PFE.N, Eli Lilly LLY.N

Elara Capital ("accumulate"; PT: 1,871 rupees) sees Leqselvi becoming Sun Pharma's second-largest product

Says that with limited treatment options, innovative drugs like Leqselvi remain important